Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study

Sponsor
LEANDRO CABRAL ZACHARIAS
Study ID
NCT02914626
Phase
PHASE3
Status
Unknown

Conditions

  • Glaucoma, Neovascular
  • Ranibizumab

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Neovascular glaucoma is a potentially blinding condition characterized by the growth of newvessels at the anterior part of the eye. This growth is driven by the overexpression of a protein called Vascular Endothelial Growth Factor (VEGF). That happens in diseases such as diabetic retinopathy or venous retinal occlusion, and lead to a fast increase in intraocular pressure (IOP). Traditional treatment include laser photocoagulation of the retina in order to decrease VEGF formation. The investigators postulate that the use of anti-VEGF intravitreal injections may accelerate recovery and decrease the need of surgery in cases of neovascular glaucoma.

Key Dates

First listed
Sep 26, 2016
Start date
Oct 31, 2016
Status verified
Sep 2016
Primary completion
Oct 31, 2017
Completion
Oct 31, 2018

Study Design

Enrollment
28 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ranibizumab
    Standard of care therapy plus intravitreal ranibizumab injections
  • Sham Comparator: Control
    Standard of care therapy

Primary Outcome Measure

Intraocular pressure [ Time Frame: 6 months ]

Central Contacts